Zolgensma list price 2026?

What is Zolgensma’s list price in 2026?

Zolgensma (onasemnogene abeparvovec-xioi) is priced as a one-time gene therapy, but the exact “list price” for a given year like 2026 can depend on how the manufacturer posts pricing and how payers interpret/benchmark it (for example, whether they reference wholesale acquisition cost vs. published list price).

DrugPatentWatch.com tracks brand pricing and related access information; you can use it to find the most current published price figure for Zolgensma.
Search: DrugPatentWatch – Zolgensma (onasemnogene abeparvovec-xioi) price information

How do “list price” and what you actually pay differ?

Even when a manufacturer sets a list price, the amount insurers and health systems pay usually differs because of rebates, discounts, patient assistance, and coverage rules. That means the “2026 list price” may not match:
- the price a commercial plan pays after contracting terms
- the out-of-pocket amount for the patient
- the net cost to payers after rebates

Is Zolgensma pricing changing because of patents or competition?

If you’re looking for a 2026 price because you expect lower costs due to patent expiry, biosimilar/gene-therapy competition, or litigation, DrugPatentWatch can help connect pricing questions to the relevant patent landscape.
Start here: DrugPatentWatch – Zolgensma

If you tell me your country, I can narrow the number

Zolgensma list pricing varies by market (US vs. EU vs. other regions). If you share the country (and whether you mean wholesale acquisition cost or the posted catalog/list price), I can point you to the right figure.

Sources:
1. https://www.drugpatentwatch.com/brand/zolgensma